Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04667559
Other study ID # 20-001
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date October 12, 2020
Est. completion date December 14, 2022

Study information

Verified date October 2023
Source Restor3D
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a prospective multicenter study located in the United States. Subjects will be implanted with an iTotal Identity Knee Replacement System and followed for 10 years post implantation.


Recruitment information / eligibility

Status Terminated
Enrollment 22
Est. completion date December 14, 2022
Est. primary completion date December 14, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Clinical condition included in the approved Indications For Use for the iTotal Identity CR KRS - Osteoarthritis, as confirmed by the investigator's assessment of disease status at screening visit that warrants a TKR procedure. Disease status is assessed by Clinical and Radiographic assessment. - Willingness to participate in the clinical study, to give informed consent, and to attend all follow-up visits - > 18 years of age with complete development of musculoskeletal structures Exclusion Criteria: - Simultaneous bilateral procedure required - BMI > 40 - Active malignancy (defined as a history of any invasive malignancy - except nonmelanoma skin cancer), unless subject has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years - Poorly controlled diabetes (defined as HbA1c >7 or Investigator discretion) - Neuromuscular conditions which prevent subject from participating in study activities - Active local or systemic infection which precludes TKR procedure - Immunocompromised in the opinion of the Investigator - Medically diagnosed fibromyalgia or similar conditions that might impact the subject's ability to differentiate source of pain - Rheumatoid arthritis or other forms of inflammatory joint disease - Loss of bone or musculature, osteonecrosis, neuromuscular or vascular compromise in the area of the joint to be operated on, to an extent that the procedure is unjustified - Diagnosed with or receiving treatment for osteoporosis that is likely to confound results in the opinion of the Investigator - Other physical disability affecting the hips, spine, or contralateral knee that is likely to confound results in the opinion of the Investigator - Severe instability due to advanced loss of osteochondral structure - Prior arthroplasty of the affected knee, including High Tibial Osteotomy (HTO) - Compromised PCL or collateral ligament - Severe fixed valgus or varus deformity of >15º - Extensor lag > 15º - Fixed flexion contracture = 15º - Unwilling or unable to comply with study requirements - Participation in another clinical study which would confound results - Allergy to any of the implant materials - Pregnant or planning to become pregnant prior to study TKR procedure (in case of pregnancy after study TKR procedure, eligibility to continue with the protocol will be reviewed)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Conformis iTotal Identity Knee Replacement System
The iTotal® Identity KRS is a tri-compartmental semi-constrained knee prosthesis composed of three components: a Femoral Component, a Tibial Component, and a Patellar Component.Using patient imaging, a patient-specific implant is designed that best meets the geometric and anatomic requirements of the specific patient. The treatment allows for the placement of a cemented metallic device designed from the patient's natural bone geometry. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation.

Locations

Country Name City State
United States Personalized Orthopedic Research Institute Boynton Beach Florida
United States Tennessee Orthopaedic Alliance Nashville Tennessee

Sponsors (1)

Lead Sponsor Collaborator
Restor3D

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain and function Measured by 2011 Knee Society Clinical Rating Score (objective knee score 0-125, function score 0-100, satisfaction score 0-40, expectation score 0-15 with higher scores meaning better outcome) 2 years post implantation
Secondary Revision rate Post implantation up to 10 years
Secondary Incidence of major procedure-related and device-related complications, including infection rate Post implantation up to 10 years
Secondary Post-operative hip-knee-ankle limb alignment (with 180 degrees being the expected outcome, plus or minus 5 degrees), if long leg x-rays available Post implantation up to 10 years
Secondary Number of patients demonstrating radiographic loosening, radiolucency Review of x-rays to subjectively determine evidence of implant disassociation with bone Post implantation up to 10 years
Secondary Length of procedure Implant procedure from time the patient enters the operating room til time the surgery is complete and patient exits the operating room (up to 6 hours)
Secondary Length of hospital stay in hours Time from patient admission to hospital before surgery til discharge from hospital (up to 72 hours)
Secondary blood loss during surgery Implant procedure from time the patient enters the operating room til time the surgery is complete and patient exits the operating room (up to 6 hours)
Secondary blood transfusion rates Implant procedure from time the patient enters the operating room til time the surgery is complete and patient exits the operating room (up to 6 hours)
See also
  Status Clinical Trial Phase
Recruiting NCT03895489 - Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses N/A
Completed NCT03660943 - A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain Phase 3
Completed NCT04531969 - Comparison of Outpatient and Inpatient Spa Therapy N/A
Completed NCT02848027 - Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment Phase 3
Completed NCT05160246 - The Instant Effect of Kinesiology Taping in Patients With Knee OA N/A
Recruiting NCT06080763 - Biomechanics and Clinical Outcomes in Responders and Non-Responders
Completed NCT03643588 - The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain N/A
Active, not recruiting NCT05100225 - Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis Phase 2
Active, not recruiting NCT04061733 - New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis N/A
Completed NCT04051489 - A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
Recruiting NCT05546541 - Epidemiology and Nutrition
Recruiting NCT05447767 - Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg Phase 2
Not yet recruiting NCT04448106 - Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis Phase 2
Not yet recruiting NCT03225911 - Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis N/A
Completed NCT05070871 - A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women N/A
Completed NCT05703087 - Positive Cueing in Knee Arthroplasty. N/A
Not yet recruiting NCT06042426 - Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population Phase 4
Completed NCT02944448 - A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee Phase 2
Terminated NCT02909257 - Motor-Sparing Femoral Nerve Block Dose Phase 4
Not yet recruiting NCT02826850 - Saphenous Nerve Radiofrequency for Knee Osteoarthritis Trial Phase 3